The Outcome

Immunovia AB was granted 4,25 Meur from the SME Instrument, HORIZON 2020, phase 2.

The Company

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases earlier and more accurately than previously possible. 

The project

The project aims to perform the clinical validation of a serum biomarker signature for the early diagnosis of pancreatic cancer. The biomarker signature is based on the world’s most advanced recombinant antibody microarray platform owned by Immunovia AB. The underlying technology is affinity proteomics. The biomarker signature hence exploits the body’s own detection network for the diagnosis of cancer. The initial retrospective clinical studies have confirmed that the biomarker signature can accurately separate pancreatic cancer patients from healthy individuals. The implication is that the signature, once validated by a robust method, has a very high potential for the short-term uptake into clinical practice.

GAEU's role

GAEU has been deeply involved in structuring the scope and configuration of the project and its budget. GAEU conducted workshops with the client and wrote the successful SME Instrument phase 2 application. GAEU also produced the Grant Agreement and reported the project to the EC.


“GAEU Consulting helped us to structure our projects based on the criterias applied in the SME instrument. During a full-day workshop we discussed the application strategy and how the clinical content was to be presented. Then GAEU wrote the application and guided us through the process. The Horizon 2020 experts in GAEU proved to be very efficient and professional in their work and had great commitment and interest in our project which resulted in a grant of EUR 4.25 million for clinical validation of a biomarker for early diagnosis of pancreatic cancer. We are very pleased with GAEU Consulting's performance and we highly recommend the company for similar efforts. GAEU Consulting is an excellent advisor suited for excellent innovation projects in the Horizon 2020! “ Mats Grahn CEO, Immunovia

Mats Grahn, VD